. 2021 Aug 11;19:238. doi: 10.1186/s12957-021-02348-6

Table 4.

Results of multivariable analysis for DFS

	Non-adjusted^a	Adjust I^b	Adjust II^c
	HR (95% CI), P value	HR (95% CI), P value	HR (95% CI), P value
Postoperative capecitabine duration	0.91 (0.86, 0.98), 0.014	0.90 (0.83, 0.98), 0.012	0.90 (0.82, 0.96), 0.006
0	1.0	1.0	1.0
≤ 12 weeks	0.52 (0.36, 0.98), 0.030	0.52 (0.35, 0.98), 0.033	0.45 (0.32, 0.90), 0.030
≤ 24 weeks	0.26 (0.19, 0.70), 0.007	0.26 (0.19, 0.70), 0.008	0.24 (0.17, 0.68), 0.005

Notes: ^aNon-adjusted model adjusted for: none

^bAdjust I adjust for: gender; age

^cAdjust II adjust for: gender; age; stage; CEA; CA199; CCI; histological type, and MMR status

Abbreviations: HR hazard ratio; CI confidence interval; CA carcinoma antigen; CEA carcinoembryonic antigen; MMR mismatch repair; CCI Charlson comorbidity index